The grapefruit polyphenol naringenin inhibits multiple cardiac ion channels.

Autor: Sanson C; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, 13 quai Jules Guesde, F-94403, Vitry-sur-Seine, France., Boukaiba R; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, 13 quai Jules Guesde, F-94403, Vitry-sur-Seine, France., Houtmann S; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, 13 quai Jules Guesde, F-94403, Vitry-sur-Seine, France., Maizières MA; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, 13 quai Jules Guesde, F-94403, Vitry-sur-Seine, France., Fouconnier S; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, 13 quai Jules Guesde, F-94403, Vitry-sur-Seine, France., Partiseti M; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, 13 quai Jules Guesde, F-94403, Vitry-sur-Seine, France., Bohme GA; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, 13 quai Jules Guesde, F-94403, Vitry-sur-Seine, France. andrees.bohme@sanofi.com.

Publikováno v: Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2022 Jun; Vol. 395 (6), pp. 735-740. Date of Electronic Publication: 2022 Apr 12.

Fluorescent- and tagged-protoxin II peptides: potent markers of the Na v 1.7 channel pain target.

Autor: Montnach J; LabEx 'Ion Channels, Science & Therapeutics', l'institut du thorax, INSERM, CNRS, UNIV NANTES, Nantes, France., De Waard S; LabEx 'Ion Channels, Science & Therapeutics', l'institut du thorax, INSERM, CNRS, UNIV NANTES, Nantes, France., Nicolas S; LabEx 'Ion Channels, Science & Therapeutics', l'institut du thorax, INSERM, CNRS, UNIV NANTES, Nantes, France., Burel S; LabEx 'Ion Channels, Science & Therapeutics', l'institut du thorax, INSERM, CNRS, UNIV NANTES, Nantes, France., Osorio N; Laboratory of Cognitive Neuroscience, UMR 7291, CNRS, Aix-Marseille University, Marseille, France., Zoukimian C; Smartox Biotechnology, Saint-Egrève, France., Mantegazza M; Université Cote d'Azur, CNRS UMR 7275, Institute of Molecular and Cellular Pharmacology, Valbonne-Sophia Antipolis, France., Boukaiba R; Sanofi R&D, Integrated Drug Discovery - High Content Biology, Vitry-sur-Seine, France., Béroud R; Smartox Biotechnology, Saint-Egrève, France., Partiseti M; Sanofi R&D, Integrated Drug Discovery - High Content Biology, Vitry-sur-Seine, France., Delmas P; Laboratory of Cognitive Neuroscience, UMR 7291, CNRS, Aix-Marseille University, Marseille, France., Marionneau C; LabEx 'Ion Channels, Science & Therapeutics', l'institut du thorax, INSERM, CNRS, UNIV NANTES, Nantes, France., De Waard M; LabEx 'Ion Channels, Science & Therapeutics', l'institut du thorax, INSERM, CNRS, UNIV NANTES, Nantes, France.; Smartox Biotechnology, Saint-Egrève, France.

Publikováno v: British journal of pharmacology [Br J Pharmacol] 2021 Jul; Vol. 178 (13), pp. 2632-2650. Date of Electronic Publication: 2021 May 14.

Quercetin is a foe in the heart by targeting the hERG potassium channel.

Autor: Zihao Lu¹, Shuwen Li¹, Rui Wei², Wenwen Li¹, Yuqian Huang¹, Tingting Yang¹, Meng Yan¹ yanmeng0727@xzhmu.edu.cn

Publikováno v: Iranian Journal of Basic Medical Sciences. Nov2024, Vol. 27 Issue 11, p1397-1404. 8p.

Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures.

Autor: Guillot E; Diabetes and Cardiovascular Unit, Sanofi R&D, Chilly-Mazarin, France (E.G., J.C.L.B., P.B., P.J.); Global Research Portfolio and Project Management, Sanofi R&D, Chilly-Mazarin, France (C.P.); Translational Science Unit, Sanofi R&D, Chilly-Mazarin, France (P.P., V.F.); In-silico design, Chilly-Mazarin, France (B.C.); and Integrated Drug Discovery, Sanofi R&D, Vitry-Sur-Seine, France (M.P.) etienne.guillot@sanofi.com., Le Bail JC; Diabetes and Cardiovascular Unit, Sanofi R&D, Chilly-Mazarin, France (E.G., J.C.L.B., P.B., P.J.); Global Research Portfolio and Project Management, Sanofi R&D, Chilly-Mazarin, France (C.P.); Translational Science Unit, Sanofi R&D, Chilly-Mazarin, France (P.P., V.F.); In-silico design, Chilly-Mazarin, France (B.C.); and Integrated Drug Discovery, Sanofi R&D, Vitry-Sur-Seine, France (M.P.)., Paul P; Diabetes and Cardiovascular Unit, Sanofi R&D, Chilly-Mazarin, France (E.G., J.C.L.B., P.B., P.J.); Global Research Portfolio and Project Management, Sanofi R&D, Chilly-Mazarin, France (C.P.); Translational Science Unit, Sanofi R&D, Chilly-Mazarin, France (P.P., V.F.); In-silico design, Chilly-Mazarin, France (B.C.); and Integrated Drug Discovery, Sanofi R&D, Vitry-Sur-Seine, France (M.P.)., Fourgous V; Diabetes and Cardiovascular Unit, Sanofi R&D, Chilly-Mazarin, France (E.G., J.C.L.B., P.B., P.J.); Global Research Portfolio and Project Management, Sanofi R&D, Chilly-Mazarin, France (C.P.); Translational Science Unit, Sanofi R&D, Chilly-Mazarin, France (P.P., V.F.); In-silico design, Chilly-Mazarin, France (B.C.); and Integrated Drug Discovery, Sanofi R&D, Vitry-Sur-Seine, France (M.P.)., Briand P; Diabetes and Cardiovascular Unit, Sanofi R&D, Chilly-Mazarin, France (E.G., J.C.L.B., P.B., P.J.); Global Research Portfolio and Project Management, Sanofi R&D, Chilly-Mazarin, France (C.P.); Translational Science Unit, Sanofi R&D, Chilly-Mazarin, France (P.P., V.F.); In-silico design, Chilly-Mazarin, France (B.C.); and Integrated Drug Discovery, Sanofi R&D, Vitry-Sur-Seine, France (M.P.)., Partiseti M; Diabetes and Cardiovascular Unit, Sanofi R&D, Chilly-Mazarin, France (E.G., J.C.L.B., P.B., P.J.); Global Research Portfolio and Project Management, Sanofi R&D, Chilly-Mazarin, France (C.P.); Translational Science Unit, Sanofi R&D, Chilly-Mazarin, France (P.P., V.F.); In-silico design, Chilly-Mazarin, France (B.C.); and Integrated Drug Discovery, Sanofi R&D, Vitry-Sur-Seine, France (M.P.)., Cornet B; Diabetes and Cardiovascular Unit, Sanofi R&D, Chilly-Mazarin, France (E.G., J.C.L.B., P.B., P.J.); Global Research Portfolio and Project Management, Sanofi R&D, Chilly-Mazarin, France (C.P.); Translational Science Unit, Sanofi R&D, Chilly-Mazarin, France (P.P., V.F.); In-silico design, Chilly-Mazarin, France (B.C.); and Integrated Drug Discovery, Sanofi R&D, Vitry-Sur-Seine, France (M.P.)., Janiak P; Diabetes and Cardiovascular Unit, Sanofi R&D, Chilly-Mazarin, France (E.G., J.C.L.B., P.B., P.J.); Global Research Portfolio and Project Management, Sanofi R&D, Chilly-Mazarin, France (C.P.); Translational Science Unit, Sanofi R&D, Chilly-Mazarin, France (P.P., V.F.); In-silico design, Chilly-Mazarin, France (B.C.); and Integrated Drug Discovery, Sanofi R&D, Vitry-Sur-Seine, France (M.P.)., Philippo C; Diabetes and Cardiovascular Unit, Sanofi R&D, Chilly-Mazarin, France (E.G., J.C.L.B., P.B., P.J.); Global Research Portfolio and Project Management, Sanofi R&D, Chilly-Mazarin, France (C.P.); Translational Science Unit, Sanofi R&D, Chilly-Mazarin, France (P.P., V.F.); In-silico design, Chilly-Mazarin, France (B.C.); and Integrated Drug Discovery, Sanofi R&D, Vitry-Sur-Seine, France (M.P.).

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2020 Aug; Vol. 374 (2), pp. 283-294. Date of Electronic Publication: 2020 May 14.

Cannabinol (CBN) Influences the Ion Channels and Synaptic-Related Genes in NSC-34 Cell Line: A Transcriptomic Study.

Autor: Trainito, Alessandra¹ (AUTHOR), Muscarà, Claudia¹ (AUTHOR), Gugliandolo, Agnese¹ (AUTHOR), Chiricosta, Luigi¹ (AUTHOR), Salamone, Stefano² (AUTHOR) federica.pollastro@uniupo.it, Pollastro, Federica² (AUTHOR), Mazzon, Emanuela³ (AUTHOR) emanuela.mazzon@irccsme.it, D'Angiolini, Simone¹ (AUTHOR)

Publikováno v: Cells (2073-4409). Sep2024, Vol. 13 Issue 18, p1573. 20p.